- Home
- QCRH vs CLDX Comparison
QCRH vs CLDX Comparison
Compare QCRH & CLDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QCRH
- CLDX
- Stock Information
- Founded
- QCRH 1993
- CLDX 1983
- Country
- QCRH United States
- CLDX United States
- Employees
- QCRH N/A
- CLDX N/A
- Industry
- QCRH Major Banks
- CLDX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- QCRH Finance
- CLDX Health Care
- Exchange
- QCRH Nasdaq
- CLDX Nasdaq
- Market Cap
- QCRH 1.4B
- CLDX 1.6B
- IPO Year
- QCRH 1993
- CLDX 2008
- Fundamental
- Price
- QCRH $80.70
- CLDX $23.78
- Analyst Decision
- QCRH Buy
- CLDX Buy
- Analyst Count
- QCRH 3
- CLDX 7
- Target Price
- QCRH $76.00
- CLDX $64.83
- AVG Volume (30 Days)
- QCRH 89.8K
- CLDX 1.1M
- Earning Date
- QCRH 01-22-2025
- CLDX 02-24-2025
- Dividend Yield
- QCRH 0.30%
- CLDX N/A
- EPS Growth
- QCRH 6.88
- CLDX N/A
- EPS
- QCRH 6.88
- CLDX N/A
- Revenue
- QCRH $341,805,000.00
- CLDX $9,976,000.00
- Revenue This Year
- QCRH N/A
- CLDX N/A
- Revenue Next Year
- QCRH $10.78
- CLDX N/A
- P/E Ratio
- QCRH $11.73
- CLDX N/A
- Revenue Growth
- QCRH 5.07
- CLDX 128.55
- 52 Week Low
- QCRH $54.37
- CLDX $22.17
- 52 Week High
- QCRH $96.08
- CLDX $53.18
- Technical
- Relative Strength Index (RSI)
- QCRH 44.87
- CLDX 41.99
- Support Level
- QCRH $75.51
- CLDX $22.17
- Resistance Level
- QCRH $81.65
- CLDX $29.05
- Average True Range (ATR)
- QCRH 1.83
- CLDX 1.57
- MACD
- QCRH 0.30
- CLDX -0.26
- Stochastic Oscillator
- QCRH 72.69
- CLDX 23.40
About QCRH QCR Holdings Inc.
QCR Holdings Inc is a multi-bank holding company. The bank operates through segments namely Commercial Banking, Wealth Management, and all other segments. The commercial bank segment is geographically divided by markets namely QCBT, CRBT, CSB, and GB. It generates revenue in the form of interest.
About CLDX Celldex Therapeutics Inc.
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527.